TAR-200

Phase 3Small molecule

Johnson & Johnson

TAR-200 is one of 57 small molecule programs targeting Urinary Bladder Neoplasms. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urinary Bladder NeoplasmsActive, not recruiting

Non-Muscle Invasive Bladder NeoplasmsActive, not recruiting

Bladder CancerActive, not recruiting

Urinary Bladder NeoplasmsPhase 3

Active, not recruiting

Non-Muscle Invasive Bladder NeoplasmsPhase 3

Active, not recruiting

Bladder CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

118 competitors in Bladder Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

52 2

Keytruda

Merck & Co.

Phase 3

27 3

Opdivo

Bristol-Myers Squibb

Phase 3

20 4

Imfinzi

AstraZeneca

Phase 3

16 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

57 6

Tecentriq

Roche

Phase 3

16 7

Trexall

Jazz Pharmaceuticals

Phase 3

12 8

Padcev

Pfizer

Phase 3

8 9

Imjudo

AstraZeneca

Phase 3

8 10

Gemzar

GGynecologic Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Urinary Bladder Neoplasms

NCT04640623

Q4 2028

Phase 3Active, not recruiting

Urinary Bladder Neoplasms

NCT04658862

Q3 2029

Phase 3Active, not recruiting

Bladder Cancer

NCT05714202

Q2 2031

Phase 3Active, not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06211764

Clinical

Trials by Indication[1]

Urinary Bladder Neoplasms3 trials

Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04640623·220 enrolled

A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04658862·518 enrolled

A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04919512·163 enrolled

Non-Muscle Invasive Bladder Neoplasms2 trials

17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06211764·272 enrolled

Pre-Approval Access US Intermediate Size Expanded Access Protocol for TAR-200 Treating Physician Use

Approved for marketing· Johnson & Johnson logo

Johnson & Johnson··NCT06877676

Urothelial Carcinoma1 trial

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT03404791·35 enrolled

Bladder Cancer1 trial

A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT05714202·1,135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for TAR-200. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAR-200 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAR-200. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

TAR-200

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Q3 2029

Q2 2031

Trials by Indication[1]

Urinary Bladder Neoplasms3 trials

Non-Muscle Invasive Bladder Neoplasms2 trials

Urothelial Carcinoma1 trial

Bladder Cancer1 trial

References

Drug Info

Quick Facts

Related News